Clinical Trial Update: A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling [Phase 1, Phase 2]

View source ↗

Summary

This pediatric Phase 1/2 trial of avapritinib in KIT- or PDGFRA-dependent solid tumors and central nervous system tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Tumor
• Solid Tumor

Drugs mentioned

• AYVAKIT (avapritinib)

Snippet

Sponsor: Blueprint Medicines Corporation | Conditions: Solid Tumor, Unspecified, Child, Relapsed Solid Neoplasm | Phase 1, Phase 2 | Status: COMPLETED